Corning has acquired from Oerlikon the worldwide exclusive rights to US Patent 5,738,825 to enable full patent enforcement for the Corning Epic system
Oerlikon is one of the world's most successful industrial high-tech companies that focuses on machine and systems engineering.
Under the new patent deal Corning has acquired Patent 5,738,825 together with its foreign counterparts, which cover microplate-based optical biosensors.
Corning had previously acquired a joint ownership right in the patent from Artificial Sensing Instruments of Switzerland as part of a broader technology exchange.
By acquiring these exclusive rights in the patent from Oerlikon, Corning will not only have the right to continue to practice the technology disclosed, but will now also have the full right to enforce the patent.
The patent is related to Corning's Epic system, a high throughput label free detection platform that consists of a SBS standard 384-well microplate with optical sensors and a HTS compatible microplate reader capable of reading up to 40,000 wells per eight hours.
The Epic system enables biochemical (small and large molecule binding) and cell-based assays, and the system has been deployed at both pharmaceutical and academic institutions.
"We are pleased to expand our portfolio of enforceable patents as we continue to invest in this exciting commercial opportunity", stated Dr Jeff Mooney, commercial technology director for Corning Life Sciences.
